Mediar Therapeutics: Funding, Investors & Team (Oct 2026)
Mediar is a biotech firm in the pre-clinical phase aiming to create remedies for the cure of fibrosis. These remedies are intended to work on significant proteins that often lead to fibrosis formation in organs that have been damaged over a long period. It was established in 2019 and has its central office in Cambridge, Massachusetts.
Mediar Therapeutics has raised $123M across 2 funding rounds on record, the most recent an undisclosed round of $37.8M announced in Dec 2025.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Mediar Therapeutics Company Profile and Key Stats
Latest funding round on record: Dec 2025.
Mediar Therapeutics Funding Rounds
Mediar Therapeutics raised $85.0M in a Series A announced in Mar 2023.
2.8 years later, an undisclosed round of $37.8M was announced in Dec 2025.
Mediar Therapeutics Founders and Leadership Team
Contact details for the Mediar Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Mediar Therapeutics Funding Compared to Other Biotechnology Startups
Mediar Therapeutics' latest round of $37.8M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Mediar Therapeutics in Biotechnology and Cambridge
Companies Similar to Mediar Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Mediar Therapeutics Funding FAQs
What does Mediar Therapeutics do?
Mediar is a biotech firm in the pre-clinical phase aiming to create remedies for the cure of fibrosis. These remedies are intended to work on significant proteins that often lead to fibrosis formation in organs that have been damaged over a long period. It was established in 2019 and has its central office in Cambridge, Massachusetts.
How much funding has Mediar Therapeutics raised?
Mediar Therapeutics has raised $123M across 2 rounds on record. The most recent is an undisclosed round of $37.8M announced in Dec 2025.
When did Mediar Therapeutics last raise funding?
Mediar Therapeutics' most recent funding round on record is an undisclosed round of $37.8M, announced in Dec 2025.
Who founded Mediar Therapeutics?
FundedIQ lists Paul Yaworsky (Founder) at Mediar Therapeutics.
Where is Mediar Therapeutics headquartered?
Mediar Therapeutics is based in Cambridge, Massachusetts, United States.
How many employees does Mediar Therapeutics have?
Mediar Therapeutics is in the 11-50 employee band.
How does Mediar Therapeutics' funding compare to other Biotechnology startups?
Mediar Therapeutics' latest round of $37.8M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Mediar Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Mediar Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.